Narmada Bio-Tech Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 01-01-2025
- Paid Up Capital ₹ 2.50 M
as on 01-01-2025
- Company Age 25 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.42 Cr
as on 01-01-2025
- Satisfied Charges ₹ 4.00 M
as on 01-01-2025
- Revenue 74.38%
(FY 2022)
- Profit -60.53%
(FY 2022)
- Ebitda 660.19%
(FY 2022)
- Net Worth 10.87%
(FY 2022)
- Total Assets 17.75%
(FY 2022)
About Narmada Bio-Tech
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹2.42 Cr. The company has closed loans amounting to ₹4.00 M, as per Ministry of Corporate Affairs (MCA) records.
Pranay Jain, Nirmala Jain, Prakash Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U51109MP1999PLC013698
- Company No.
013698
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
18 Aug 1999
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Nimar, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Narmada Bio-Tech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prakash Jain  | Managing Director | 31-Aug-2007 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pranay Jain | Director | 18-Aug-1999 | Current |
| Nirmala Jain | Director | 18-Aug-1999 | Current |
| Rachna Jain | Director | 18-Aug-1999 | Current |
Financial Performance of Narmada Bio-Tech.
Narmada Bio-Tech Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 74.38% increase. The company also saw a substantial fall in profitability, with a 60.53% decrease in profit. The company's net worth Soared by an impressive increase of 10.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Narmada Bio-Tech?
In 2019, Narmada Bio-Tech had a promoter holding of 90.80% and a public holding of 9.20%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 31 Oct 2023 | ₹2.07 M | Open |
Hdfc Bank Limited Creation Date: 12 Jul 2016 | ₹2.21 Cr | Open |
Bank Of India Creation Date: 08 Mar 2011 | ₹4.00 M | Satisfied |
How Many Employees Work at Narmada Bio-Tech?
Unlock and access historical data on people associated with Narmada Bio-Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Narmada Bio-Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Narmada Bio-Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
